Trials / Completed
CompletedNCT05478590
A Study to Describe Treatment Patterns of Advanced Breast Cancer in Poland in the Real-world Data Setting
HR POSITIVE, HER 2 NEGATIVE ADVANCED BREAST CANCER- TREATMENT PATTERNS IN POLAND - HABER STUDY
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 440 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is descriptive and aims to characterize the treatment patterns of advanced breast cancer in Poland in the real-world data setting. The main goals are to assess the current treatment patterns of hormone receptor-positive (HR+) Human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer and their changes in clinical practice and relate them to patients' demographics, disease characteristics, type of other therapies used in patients as well as disease progression and visceral crisis occurrence.
Conditions
Timeline
- Start date
- 2021-11-22
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
- First posted
- 2022-07-28
- Last updated
- 2026-04-03
Locations
19 sites across 1 country: Poland
Source: ClinicalTrials.gov record NCT05478590. Inclusion in this directory is not an endorsement.